Eiger BioPharmaceuticals

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare and ultra-rare diseases. Headquartered in Palo Alto, California, Eiger's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials aimed at treating hepatitis delta virus (HDV) infection. The company's pipeline also includes Lambda, which targets type III interferon receptors and is in Phase 2 trials for HDV, as well as Lonafarnib for progeria and progeroid laminopathies. Additionally, Eiger is developing Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia and is also in Phase 2 for congenital hyperinsulinism. With a focus on addressing significant unmet medical needs, Eiger aims to deliver innovative and effective therapies to patients.